Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07311772
Recruiting Phase 3

Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid

NCT07311772 · tracked via the Priya Life Science China tracker
Sponsor
Sun Yat-sen University
Phase
Phase 3
Started
2025-12-16
Last updated
2026-05-07

Condition(s) studied

Nasopharyngeal Cancinoma (NPC)Radiation-induced Oral Mucositis

Investigational drug(s) / intervention(s)

Houyanqing Oral LiquidConventional Treatment for Radiation-Induced Oral Mucositis

Houyanqing Oral Liquid: Houyanqing Oral Liquid is a Chinese herbal preparation formulated with Achyranthes aspera L., Kalimeris indica (L.) Sch.-Bip., Plantago asiatica L., and Carpesium abrotanoides L.. For this study, it is used in nasopharyngeal carcinoma patients receiving radical radiotherapy: the dosage is 10mL per administration, 4 times daily. The medication is initiated prior to radiotherapy and continued until the completion of radiotherapy, with the purpose of preventing and treating radiation-induced oral mucositis.

Conventional Treatment for Radiation-Induced Oral Mucositis: This intervention refers to the conventional management measures for radiation-induced oral mucositis (RIOM) in nasopharyngeal carcinoma patients undergoing radical radiotherapy, including three modules: 1) Oral hygiene management; 2) Epithelial repair promotion; 3) Symptomatic support. These measures are implemented throughout the radiotherapy period to alleviate RIOM-related symptoms.

Study summary

To explore the efficacy of Houyanqing Oral Liquid combined with conventional treatment in preventing and treating radiation-induced oral mucositis, so as to improve the quality of life of nasopharyngeal carcinoma patients received radiotherapy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Staged as Stage I-IV according to the 9th edition of the TNM Classification of Malignant Tumors formulated by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC); 2. Age: 18 to 75 years old; 3. Karnofsky Performance Status (KPS) score ≥ 80 before treatment; 4. No oral diseases (such as oral mucositis or salivary gland damage) before radiotherapy; 5. Requiring radical radiotherapy; 6. The patient has signed the informed consent form and is willing and able to comply with the study's follow-up visits, treatment plan, laboratory tests, and other research procedures. Exclusion Criteria: 1. Patients with confirmed tumor recurrence, distant tumor metastasis, or who have received other anti-tumor treatments; 2. Previous history of head and neck radiotherapy; 3. Known allergy to the drugs used in this study (Houyanqing Oral Liquid, any conventional treatment drugs); 4. Local use of Houyanqing Oral Liquid, Recombinant Human Epidermal Growth Factor (rhEGF) Topical Solution, Vitamin B12 Solution, or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) mouthwash in the oral cavity within one month before enrollment; 5. Comorbidities requiring long-term treatment with immunosuppressive drugs, or systemic/local use of corticosteroids at immunosuppressive doses before enrollment; 6. HIV-positive patients; 7. Pregnant women or lactating women; 8. Patients with severe mental illnesses; 9. Patients with severe cardio-cerebrovascular diseases, endocrine disorders, infectious diseases, or other tumors.

Primary outcome measure(s)

  • Incidence of ≥ Grade II radiation-induced oral mucositis — From the start of radical radiotherapy to the 3 months after the completion of radiotherapy
    The proportion of patients in the group who develop Grade II or above radiation-induced oral mucositis from the start of radiotherapy. The degree of oral mucosal damage is evaluated according to the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) diagnostic and grading criteria for radiation-induced oral mucositis.

Trial sites (16)

FacilityCityRegionStatus
Cancer Hospital Chinese Academy of Medical Science Beijing Beijing Municipality Recruiting
Fujian Medical University Cancer Hospital Fuzhou Fujian Recruiting
Sun Yat-sen University Cancer Center Guangzhou Guangdong Recruiting
Affiliated Cancer Hospital & Institute of Guangzhou Medical University Guangzhou Guangdong Recruiting
Cancer Hospital of Shantou University Medical College Shantou Guangdong Recruiting
Fifth Affiliated Hospital of Sun Yat-sen University Zhuhai Guangdong Recruiting
Cancer Hospital of Guangxi Medical University Nanning Guangxi Recruiting
Wuzhou Red Cross Hospital Wuzhou Guangxi Recruiting
Xiangya Hospital of Central South University Changsha Hunan Recruiting
Hunan Cancer Hospital Changsha Hunan Recruiting
The First People's Hospital of Changzhou Changzhou Jiangsu Recruiting
Eye & ENT Hospital of Fudan University Shanghai Shanghai Municipality Recruiting
West China Hospital of Sichuan University Chengdu Sichuan Recruiting
The First Affiliated Hospital of Kunming Medical University Kunming Yunnan Recruiting
Yunnan Cancer Hospital Kunming Yunnan Recruiting
Zhejiang Cancer Hospital Hangzhou Zhengjiang Recruiting

More Sun Yat-sen University trials in China

Sodium Bicarbonate for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma. Active, not recruiting
A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL Recruiting
Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC Starting soon
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression Enrolling by invitation
Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma Recruiting

Other trials for the same condition

Sodium Bicarbonate for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma. Active, not recruiting
Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma Recruiting
Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy Recruiting
Development and Validation of a Deep Learning Model to Predict Distant Metastases in Nasopharyngeal Carcinoma Using Whole Slide Imaging and MRI Recruiting
Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma. Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07311772 on ClinicalTrials.gov ↗ ← All trials in China